Frequent hyperactivation and deregulation of the phosphoinositide 3-kinase (PI3K)/ AKT/ mammalian target of rapamycin (mTOR) pathway in cancer has made it one of the most investigated therapeutic targets in tumor therapy. Here, PIK3CA is linked to neoplasm.